---
layout: default
title: Lactic Acid
parent: Model Prediction Only (L5)
nav_order: 517
evidence_level: L5
indication_count: 10
---

# Lactic Acid
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Lactic Acid: From an Unspecified Approved Indication to Atypical Coarctation of Aorta

## One-Sentence Summary

Lactic acid is marketed in Canada in three single-ingredient products (PRISMASOL and PRISMOCAL solutions), but the compiled data do not state an approved indication for them.
The TxGNN model predicts it may be effective for **atypical coarctation of aorta**, with a very high score but **no clinical trials and no directly relevant publications** supporting this direction.
The evidence is model prediction only, and the available data suggest the prediction is probably a graph artifact rather than real biology.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in the data compiled for this report |
| Predicted New Indication | Atypical coarctation of aorta |
| TxGNN Prediction Score | 99.59% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 3 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Lactic acid is a naturally occurring metabolite. In Canada it is marketed in three single-ingredient products with the brand names PRISMOCAL and PRISMASOL, but the data compiled for this report do not describe their approved use.

On the biology, a plausible link to the predicted indication is hard to find. Atypical coarctation of the aorta is a structural congenital anomaly managed surgically or by catheter intervention. Lactic acid has no recognised mechanism that would correct such a defect. The very high TxGNN score (99.59%) most likely reflects the way the knowledge graph connects nearby nodes rather than a true pharmacological relationship. The prediction should be treated as a hypothesis-generating signal at best.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available for the top-ranked indication.

The second-ranked prediction, aortic malformation (score 99.35%), returned 14 publications. None tests lactic acid as a therapy. They are perioperative lactate-biomarker studies in paediatric cardiac surgery, biodegradable device and stent studies, and an animal study of aortic wall metabolism. They offer no support for a therapeutic role.

## Canada Market Information

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 02274876 | PRISM0CAL | Not stated | Not stated |
| 02243095 | PRISMASOL 0 | Not stated | Not stated |
| 02277476 | PRISMASOL 4 | Not stated | Not stated |

## Safety Considerations

- **Drug Interactions**: 17 interactions were identified, all graded Moderate or Minor.
  - **Moderate (10)**: doxycycline, tetracycline, minocycline, demeclocycline, oxytetracycline, acetylsalicylic acid, sodium salicylate, ephedrine (including nasal), and pseudoephedrine.
  - **Minor (7)**: sulfonylureas (chlorpropamide, tolazamide, glipizide, glyburide, acetohexamide, tolbutamide) and methotrexate.

Please refer to the package insert for warnings and contraindications.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests on a model score alone, with no trials, no relevant literature, and no plausible mechanism linking lactic acid to a structural aortic anomaly. The other nine top-ranked predictions are also L5 and also rated Hold. Several are structural congenital defects with no plausible mechanism. For eye disease, one report suggests lactic acid may promote choroidal neovascularization, which points toward possible harm rather than benefit.

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications, which are currently missing and block safety screening
- Mechanism of action data for lactic acid
- The approved indications and dosage forms for the three Canadian products
- Any direct preclinical or clinical evidence that lactic acid affects the predicted disease. Without it, resources are better spent on other candidates.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

